Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma.

ABSTRACT:

Background

Cabozantinib is among the most potent tyrosine kinase inhibitors (TKIs) FDA-approved for metastatic renal cell carcinoma (mRCC). Effective treatments after progression on cabozantinib salvage therapy are limited. Dose escalation for other TKIs has been shown to afford added disease control.

Objective

We sought to evaluate whether dose escalation of cabozantinib (Cabometyx^®) from conventional doses in select patients with limited treatment options offered additional disease control. We asked how cabozantinib dose increases may affect circulating drug levels.

Methods

We identified patients with mRCC at the University of Texas Southwestern Medical Center who were treated with cabozantinib dose escalation to 80 mg after progressing on conventional ca

SUBMITTER: Sharma A 

PROVIDER: S-EPMC9894028 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature